Cargando…

Synthesis and Evaluation of (177)Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells

The peptide-receptor radionuclide therapy (PRRT) is a successful approach for selectively delivering radiation within tumor sites through specific recognition of radiolabeled peptides by overexpressed receptors on cancer cell surfaces. The efficacy of PRRT could be improved by using polymeric radio-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibbens-Bandala, Brenda, Morales-Avila, Enrique, Ferro-Flores, Guillermina, Santos-Cuevas, Clara, Luna-Gutiérrez, Myrna, Ramírez-Nava, Gerardo, Ocampo-García, Blanca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835492/ https://www.ncbi.nlm.nih.gov/pubmed/31569625 http://dx.doi.org/10.3390/polym11101572

Ejemplares similares

Chemo-radiotherapy with (177)Lu-PLGA(RGF)-CXCR4L for the targeted treatment of colorectal cancer
por: Cruz-Nova, Pedro, et al.
Publicado: (2023)

(177)Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
por: Santos-Cuevas, Clara, et al.
Publicado: (2018)

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Synthesis and Evaluation of (177)Lu-DOTA-PD-L1-i and (225)Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Fluorescent, Plasmonic, and Radiotherapeutic Properties of the (177)Lu–Dendrimer-AuNP–Folate–Bombesin Nanoprobe Located Inside Cancer Cells
por: Mendoza-Nava, Héctor, et al.
Publicado: (2017)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Radioligand Therapy with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
por: Durma, Adam Daniel, et al.
Publicado: (2023)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases
por: Fernández, René, et al.
Publicado: (2021)

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014)

[(99m)Tc]Tc-iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients
por: Coria-Domínguez, Luis, et al.
Publicado: (2022)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

Biodistribution and post-therapy dosimetric analysis of [(177)Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results
por: Khawar, Ambreen, et al.
Publicado: (2019)

Radiation exposure assessment of nuclear medicine staff administering [(177)Lu]Lu-DOTA-TATE with active and passive dosimetry
por: Riveira-Martin, Mercedes, et al.
Publicado: (2023)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Optimization of (177)Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
por: Cankaya, Aylin, et al.
Publicado: (2023)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

Physicochemical Evaluation of Lyophilized Formulation of p-SCN-Bn-DOTA- and p-SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy
por: Ackova, Darinka Gjorgieva, et al.
Publicado: (2016)

Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer
por: Cruz-Nova, Pedro, et al.
Publicado: (2022)

[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Glover, Matthew, et al.
Publicado: (2021)

In vitro characterisation of [(177)Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
por: Hull, Ashleigh, et al.
Publicado: (2023)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

Development of (177)Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen
por: Carpanese, Debora, et al.
Publicado: (2020)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5f574dqi19ilkb8rfod8h2elts